{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:29:58Z","timestamp":1792441798998,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejpb.2023.06.006","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T16:22:19Z","timestamp":1687623739000},"page":"240-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease"],"prefix":"10.1016","volume":"189","author":[{"given":"Renae K.","family":"Barr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce W.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia B.","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle C.","family":"Musk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Page-Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin T.","family":"Batty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Carapetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejpb.2023.06.006_b0005","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2102074","article-title":"Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease","volume":"386","author":"Beaton","year":"2022","journal-title":"New England J. Med."},{"issue":"11","key":"10.1016\/j.ejpb.2023.06.006_b0010","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.109.191959","article-title":"Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis","volume":"119","author":"Gerber","year":"2009","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ejpb.2023.06.006_b0015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis","year":"2005","journal-title":"Lancet Infect. Dis."},{"issue":"8","key":"10.1016\/j.ejpb.2023.06.006_b0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJMoa1603693","article-title":"Global, Regional, and National Burden of Rheumatic Heart Disease, 1990\u20132015","volume":"377","author":"Watkins","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.006_b0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1017\/S0950268800003514","article-title":"Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population?","volume":"124","author":"Carapetis","year":"2000","journal-title":"Epidemiol. Infect."},{"issue":"19","key":"10.1016\/j.ejpb.2023.06.006_b0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016851","article-title":"Contemporary Incidence and Prevalence of Rheumatic Fever and Rheumatic Heart Disease in Australia Using Linked Data: The Case for Policy Change","volume":"9","author":"Katzenellenbogen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejpb.2023.06.006_b0035","article-title":"A new insight about pharmaceutical dosage forms for benzathine penicillin G","volume":"27","author":"Silva","year":"2009","journal-title":"Revista de Ci\u00eancias Farmac\u00eauticas B\u00e1sica e Aplicada"},{"issue":"11","key":"10.1016\/j.ejpb.2023.06.006_b0040","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1128\/AAC.02744-14","article-title":"A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejpb.2023.06.006_b0045","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1542\/peds.69.4.452","article-title":"Serum penicillin concentrations after intramuscular administration of benzathine penicillin G in children","volume":"69","author":"Ginsburg","year":"1982","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejpb.2023.06.006_b0050","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1128\/AAC.38.5.1203","article-title":"Penicillin concentrations after increased doses of benzathine penicillin G for prevention of secondary rheumatic fever","volume":"38","author":"Currie","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.ejpb.2023.06.006_b0055","doi-asserted-by":"crossref","first-page":"e25308","DOI":"10.1371\/journal.pone.0025308","article-title":"Serum Penicillin G Levels Are Lower Than Expected in Adults within Two Weeks of Administration of 1.2 Million Units","volume":"6","author":"Broderick","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejpb.2023.06.006_b0060","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13346-018-0482-z","article-title":"Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD)","volume":"8","author":"Montagnat","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"issue":"5","key":"10.1016\/j.ejpb.2023.06.006_b0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrcardio.2012.7","article-title":"World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease\u2014an evidence-based guideline","volume":"9","author":"Rem\u00e9nyi","year":"2012","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.006_b0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/2395-5414.157554","article-title":"Evolution, evidence and effect of secondary prophylaxis against rheumatic fever","volume":"1","author":"Wyber","year":"2015","journal-title":"J. Pract. Cardiovascular Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2023.06.006_b0075","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s13346-016-0313-z","article-title":"Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever","volume":"6","author":"Wyber","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.006_b0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7326\/0003-4819-60-2-31","volume":"20","author":"Wood","year":"1964","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejpb.2023.06.006_b0085","unstructured":"Acute rheumatic fever and rheumatic heart disease in Australia 2016\u20132020. 2022, Australian Institute of Health and Welfare: Canberra."},{"issue":"10","key":"10.1016\/j.ejpb.2023.06.006_b0090","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1093\/jac\/dkaa282","volume":"75","author":"Kado","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2023.06.006_b0095","unstructured":"D. Sika-Paotonu, et al., The BPG reformulation preferences of children and young people \u2013 an interim analysis, in: Xavier Louisiana School of Pharmacy Health Disparities Conference, New Orleans, 2019."},{"issue":"19","key":"10.1016\/j.ejpb.2023.06.006_b0100","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.2174\/1381612822666160217141049","article-title":"The Production of Solid Dosage Forms from Non-Degradable Polymers","volume":"22","author":"Major","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.006_b0105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/2231-4040.133431","article-title":"Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies","volume":"5","author":"Navitha","year":"2014","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"10.1016\/j.ejpb.2023.06.006_b0110","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0954-6111(01)90023-X","article-title":"Re-evaluating current antibiotic therapy","volume":"95","author":"Craig","year":"2001","journal-title":"Respir. Med."},{"issue":"7","key":"10.1016\/j.ejpb.2023.06.006_b0115","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/jac\/dkz076","article-title":"A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease: new insights for improved secondary prophylaxis strategies","volume":"74","author":"Hand","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.ejpb.2023.06.006_b0120","doi-asserted-by":"crossref","first-page":"e0009399","DOI":"10.1371\/journal.pntd.0009399","article-title":"High risk of early sub-therapeutic penicillin concentrations after intramuscular benzathine penicillin G injections in Ethiopian children and adults with rheumatic heart disease","volume":"15","author":"Ketema","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"10","key":"10.1016\/j.ejpb.2023.06.006_b0125","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1093\/jac\/dkac231","article-title":"Population pharmacokinetic study of benzathine penicillin G administration in Indigenous children and young adults with rheumatic heart disease in the Northern Territory, Australia","volume":"77","author":"Kado","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.ejpb.2023.06.006_b0130","doi-asserted-by":"crossref","first-page":"e064022","DOI":"10.1136\/bmjopen-2022-064022","article-title":"Study protocol for controlled human infection for penicillin G against Streptococcus pyogenes: a double-blinded, placebo-controlled, randomised trial to determine the minimum concentration required to prevent experimental pharyngitis (the CHIPS trial)","volume":"12","author":"Hla","year":"2022","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.ejpb.2023.06.006_b0135","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1517\/17425247.5.3.291","article-title":"Lipid implants as drug delivery systems","volume":"5","author":"Kreye","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"issue":"9","key":"10.1016\/j.ejpb.2023.06.006_b0140","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.3390\/ijms10094033","article-title":"Degradability of Polymers for Implantable Biomedical Devices","volume":"10","author":"Lyu","year":"2009","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.006_b0145","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nbt0298-153","article-title":"Improving protein therapeutics with sustained-release formulations","volume":"16","author":"Putney","year":"1998","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.ejpb.2023.06.006_b0150","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1586\/17434440.5.5.623","article-title":"Contraceptive devices: subcutaneous delivery systems","volume":"5","author":"Benagiano","year":"2008","journal-title":"Expert Rev. Med. Dev."},{"issue":"6","key":"10.1016\/j.ejpb.2023.06.006_b0155","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3390\/pharmaceutics12060567","article-title":"Injectable Lipid-Based Depot Formulations: Where Do We Stand?","volume":"12","author":"Rahnfeld","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.06.006_b0160","unstructured":"C. Engineer, J.K. Parikh, A. Raval, Hydrolytic Degradation Behavior of Biodegradable Polymers from Controlled Drug Delivery System, 2011."},{"issue":"4","key":"10.1016\/j.ejpb.2023.06.006_b0165","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0079-6700(94)90030-2","article-title":"Biodegradable polymers for biomedical uses","volume":"19","author":"Hayashi","year":"1994","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.ejpb.2023.06.006_b0170","first-page":"p. 79+","article-title":"Review on hydrolytic degradation behavior of biodegradable polymers from controlled drug delivery system","volume":"25","author":"Engineer","year":"2011","journal-title":"Trends Biomater. Artif. Organs"},{"key":"10.1016\/j.ejpb.2023.06.006_b0175","first-page":"14","article-title":"Degradation of Poly(D, L-lactide-co-glycolide) 50: 50 Implant in Aqueous Medium","author":"Darestani","year":"2005","journal-title":"Iran Polym. J."},{"issue":"3","key":"10.1016\/j.ejpb.2023.06.006_b0180","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.ejpb.2023.06.006_b0185","unstructured":"Australian Government. Australian code for the care and use of animals for scientific purposes 2013; Available from: https:\/\/www.nhmrc.gov.au\/about-us\/publications\/australian-code-care-and-use-animals-scientific-purposes#toc__167."},{"issue":"8","key":"10.1016\/j.ejpb.2023.06.006_b0190","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00252-17","article-title":"Penicillin Dried Blood Spot Assay for Use in Patients Receiving Intramuscular Benzathine Penicillin G and Other Penicillin Preparations To Prevent Rheumatic Fever","volume":"61","author":"Page-Sharp","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejpb.2023.06.006_b0195","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2885.1990.tb00780.x","article-title":"Comparative benzylpenicillin pharmacokinetics in the dromedary Camelus dromedarius and in sheep","volume":"13","author":"Oukessou","year":"1990","journal-title":"J. Vet. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.ejpb.2023.06.006_b0200","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.biomaterials.2005.09.019","article-title":"The in vivo degradation, absorption and excretion of PCL-based implant","volume":"27","author":"Sun","year":"2006","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2023.06.006_b0205","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jconrel.2021.10.021","article-title":"Long-acting biodegradable implant for sustained delivery of antiretrovirals (ARVs) and hormones","volume":"340","author":"Li","year":"2021","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.ejpb.2023.06.006_b0210","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s11095-016-1904-6","article-title":"A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis","volume":"33","author":"Schlesinger","year":"2016","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.ejpb.2023.06.006_b0215","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1128\/AAC.38.5.1203","article-title":"Penicillin concentrations after increased doses of benzathine penicillin G for prevention of secondary rheumatic fever","volume":"38","author":"Currie","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejpb.2023.06.006_b0220","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/clinids\/17.3.491","article-title":"Clinical Pharmacokinetics of Continuous Intravenous Administration of Penicillins","volume":"17","author":"Visser","year":"1993","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.006_b0225","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0022-3476(89)80352-X","article-title":"Pharmacokinetics of benzathine penicillin G: Serum levels during the 28 days after intramuscular injection of 1,200,000 units","volume":"115","author":"Kaplan","year":"1989","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ejpb.2023.06.006_b0230","unstructured":"R. Wyber, Global Status of BPG Report. RHD Action."},{"issue":"7","key":"10.1016\/j.ejpb.2023.06.006_b0235","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/jac\/dkac124","article-title":"Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modelling","volume":"77","author":"Tait","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2023.06.006_b0240","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkac231","article-title":"Population pharmacokinetic study of benzathine penicillin G administration in Indigenous children and young adults with rheumatic heart disease in the Northern Territory, Australia","author":"Kado","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ejpb.2023.06.006_b0245","series-title":"Endocrinology: Adult and Pediatric (Seventh Edition)","first-page":"2297","article-title":"Contraception","author":"Glasier","year":"2016"},{"key":"10.1016\/j.ejpb.2023.06.006_b0250","doi-asserted-by":"crossref","unstructured":"B.W. Barber, Development of a sustained release implant of high-dose benzathine penicillin G for prophylactic treatment of rheumatic heart disease, 2023.","DOI":"10.1016\/j.ejpb.2023.06.006"},{"issue":"539","key":"10.1016\/j.ejpb.2023.06.006_b0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax3799","article-title":"Interleukin 17 and senescent cells regulate the foreign body response to synthetic material implants in mice and humans","volume":"12","author":"Chung","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejpb.2023.06.006_b0260","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-319-18603-0_6","article-title":"Foreign Body Reaction to Subcutaneous Implants","volume":"865","author":"Kastellorizios","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.006_b0265","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00266-018-1280-1","article-title":"Clinical Application of Three-Dimensionally Printed Biomaterial Polycaprolactone (PCL) in Augmentation Rhinoplasty","volume":"43","author":"Park","year":"2019","journal-title":"Aesthetic Plast. Surg."},{"issue":"6","key":"10.1016\/j.ejpb.2023.06.006_b0270","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1163\/156856208784522083","article-title":"Reduced foreign body reaction to implanted biomaterials by surface treatment with oriented osteopontin","volume":"19","author":"Liu","year":"2008","journal-title":"J. Biomater. Sci. Polym. Ed."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.006_b0275","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s13346-017-0408-1","article-title":"Silica microparticles for sustained zero-order release of an anti-CD40L antibody","volume":"8","author":"Tyagi","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"issue":"6","key":"10.1016\/j.ejpb.2023.06.006_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/nano11061578","article-title":"Sustained In-Vivo Release of Triptorelin Acetate from a Biodegradable Silica Depot: Comparison to Pamorelin((R)) LA","volume":"11","author":"Forsback","year":"2021","journal-title":"Nanomaterials (Basel)"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:54:03Z","timestamp":1760547243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123001595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":56,"alternative-id":["S0939641123001595"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.06.006","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}